Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the VectivBio's Fiscal Year 2022 Results Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Patrick Malloy, Senior Vice President, Investor Relations. ahead. go Please

Patrick Malloy

December good results which and Company Welcome today's which release on full-year to review we available this Thank a is progress issued will morning, across provide during press ended the for we financial our the website. XXXX. an call Earlier our morning financial you, summarizing results everyone. XX, and update our and Company, on the

expectations, make remind of to today's that and statements forward-looking about constitute everyone future provisions Actual the under we purposes these will like forward-looking as I'd discussed any the risk Litigation discussion, may these factors update statements our materially XXXX. of are by obligation Private our during of plans, to Harbor the including indicated that forward-looking a filings, prospects Securities we for Act Reform SEC not the results in statements, under and from various differ statements. those result important factors, Safe

call our Harris, our with Officer. me Omar Kevin Chief and are along Joining Khwaja; Luca Medical Officer; Officer; today's Chief Claudia Chief our Financial Santarelli, on Officer, Chief D'Augusta, Executive Commercial

the Following we'll the up to question-and-answer remarks, session. open a call prepared

to Now, turn to the call Santarelli. I'd over like Luca

Luca Santarelli

for joining Thank you, and today. thanks to Pat, us everyone

living For serious VectivBio that late people stage life-transforming rare the is potentially those biopharmaceutical diseases. focused first our with for is hearing for therapies company story time, a growing on developing

expertise relentless and treatments needs driven We developing with are to to a both diseases living scientific lives a of individual are patients. transformational by in rare deep team that the meaningful people of the of a with individuals make passion tailored difference by

this of in with could broad gastrointestinal intestinal range including next-generation the short lives analog GLP-X suffering of transform syndrome that patient believe lead apraglutide, development of to potential Host GLP-X bowel unique diseases, XXXX, and Graft Disease molecule promise have full our pharmacology SBS-IF apraglutide the and Acute people In rare aGvHD. severe, our developing tailored the strategy. the also Thanks versus made of progress We failure that class. bears or we tremendous from a unlocking or a

despite deal QX created focused that of our execution were corporate with also milestones We and we program the R&D achieve 'XX commercialize the designed able we in stage and and environment. challenges Pharmaceutical, for next to positioned Kasei Japan key to In a in biotech both towards on growth. ourselves goals. develop strategic XXXX, we Japan. our licensing And Asahi apraglutide In signed XXXX, several

the in in announced of first patients. Colon-in-Continuity we with STARGAZE, currently In interim concept under-served CIC, patients promising QX, study, of U.S. an recruiting patients and kind proof majority of first a dosing the study Nutrition In of in two data its from Europe. or QX, which the announced STARS months our represents study we anatomy acute six GvHD across SBS-IF

equity a the we Phase the of finally, be and months November, transactions. the cash into stratum VectivBio raising completion The for strengthened STARS of we XXXX, enrollment announced financial $XXX our position Colon-in-Continuity XX a In a over both And provides study. Phase by cash total position runway to which X X million pivotal current after is with the results. non-dilutive of

next year believe six early X Phase for STARS clinical in all specifically, May, scientific the months. conference. that will from a STARS, data will Nutrition presented STARS at be XXXX transformational several an Nutrition, from and months We the STARGAZE, VectivBio readout upcoming More be with over

data where there intestinal of is reduce improve of absorption can apraglutide the that and in subtypes In need use anatomical parenteral demonstrate to of supporting the patients Gattex. with aims support limited SBS-IF study This Colon-in-Continuity. SBS

At patients, failure anticipated last by the this reach of STARS to our current point, X We enrollment in this those based quarter. target issue us Phase plan in new on study, program patient. screen closed currently our SBS-IF randomization completion end the of to following enable of rates. the the apraglutide under will have a Nutrition progress we as enrollment screening is of the of assessment press release Alongside the the

damage, onto has to happy enrolled will us we interim perform and by of filing This GvHD, the rationale Acute and to would immunological regenerative is the inflammatory GI to where outcome first Phase mortality. one of the patients all the in Moving necessary the Acute that the become currently of where pre-planned therapy apraglutide to properties end development this A conditions, approach. strategy the I'm establish critical leading the treatment non-immunosuppressive inform positive GI explore to the the QX. in is announce of to help potential STARGAZE address main also therapeutic GvHD disease program apraglutide STARGAZE which most analysis complications healing our of have analysis GI X other

Dr. Officer, share Now, who turn Omar, pipeline our like will to call our I details on Omar would over you. to over Medical additional to progress. Khwaja, Chief the

Omar Khwaja

Thanks, morning, everyone. Luca, and good

I on will out apraglutide more we'll year. detail provide read that of of the studies major this some

study remains this with or in colon CIC. months a patients and the where These STARS all data is with present Nutrition May patients of on STARS connected are through Colon-in-Continuity in on week six functional intestine nine suggested small Nutrition Chicago enrolled represent to SBS-IF patients. the in study. patients important As will SBS-IF X, majority first-ever remnant the our we dedicated

metabolic patients the XX% is same of six five a study The Phase CIC effect robust same in first main XXXX, components. October study period. very PS used study leading the on and X in data reduction after has The of interim assessment which the parenteral support We algorithm with reduction component dose was an applied. volume PS The a our demonstrated released at specific six balance in treated were whom at months months. two to participants

data present point. at all will from We patients time this

assess to also weeks apraglutide's has effect XX of weeks a analysis on of which study compared to and point component, early late is time four an quantitatively at balance The intestinal baseline. the an absorption time point exploratory metabolic

of We the supports early four where show DDW positive data measures data week from that absorption. will timepoint apraglutide effects we of report on to at aim

represents available best XX with Mid-year, Disease. Phase acute on up we unmet acute We're and a patients with patients very STARGAZE therapy, X top low a interim high to first apraglutide level Ruxolitinib. high apraglutide study corticosteroids of who with need. at on were months concept Even has This dose steroid-refractory recruiting or steroid-refractory Graft-Versus-Host mortality XX% of donor of will the GvHD six GI the medical a data disorder is treated patients and proof of attack analysis of from consequence GI T-cells in have tract. in by our a of

interim study response analysis durability XX response The for XX first will in patients this randomized. rates, tolerability, All of days. to include least been this at patients treated the interim support have safety, and analysis in

from can GvHD. Acute program pivotal the STARGAZE the Positive in support data

see the for we immune or immune disease in ulcerative In and in inflammatory GI that proof other as addition, data unlock such as the conditions GI this an potential tract principle apraglutide of may Crohn's disease. of colitis

for study QX, will Phase our we and in clinical for SBS-IF. of stratification STARS XX% ever with X STARS support. XX% dependent and parenteral the Positive in prospective are study largest form will with with the of patients on Finally, patients include conducted application use have basis apraglutide from is who stoma. approval CIC data data to our patients, patients a it's in SBS-IF SBS XXX recruiting by

are a Study randomized ratio. weeks, also XX participants several the benefits treated In weeks. kilos, X.X and whole apraglutide, secondary and XX a XX single The population, weeks milligrams XX after parenteral with in the who are specific primary X weeks are for study assessed alpha two-to-one anatomy are CIC key with six below thought volume for controlled of in is placebo endpoints bodies to weigh reduction placebo for support weeks. patients dose phase, the patients to months controlled treated while common XX milligrams XX accrue that patients for at endpoint

In year to and also the completed further of from We the STARS as days suite well support patients endpoints enteral a All benefits establish extensive Recruitment of October parenteral on an meaningful CIC with clinical in arm remained patient roll into secondary open Extend extension eligible the to period the full off XXXX. STARS into track. such treatment important addition label to has outcomes recruitment reported autonomy, XX-week are the study includes apraglutide. study. clinically over

are We arm, recruitment into completing the which Stoma close treatment XX-week to requires period. a

we target. Study top have closed reach screening been line of mentioned, extremely has Luca forward we currently good retention As results our look will enrollment those and in patients, us as QX. enable in to our screening to new

updates are indications. from have the clinical in actively apraglutide Acute We additional forward strong key to look providing SBS, and exploring in the progress of readouts We in development as XXXX. as the well made GvHD

Kevin our Harris. turn Chief over the call I'll Officer, Now, to Commercial

Kevin Harris

Thanks, Omar.

and XXXX, laying been advancing foundation three made strategy our have a progress past apraglutide launch over strong we've years. for the In great commercialization plans and for

have We key areas. on focused four been

first market development. The is area

good challenges provide with and our will We for the of support messaging an treatment understanding parenteral plans. living and a lessons foundation first-generation of unmet GLP-X and learned the from have market which needs chronic important development

we strategy have product results. apraglutide, time Phase for area long of activities building where in advance second is The completed branding and key key our X lead

key third market access. The is area

market significant had has in generation informed data our European payers, access value U.S. which have our and engagement We plan. strategy with and

apraglutide. patient-centric our the support infrastructure building of is area key fourth launch to successful The

design for a high-touch to the enable services day experience and work model one. with completed attribution have a from apraglutide We patient positive

and designed also IT infrastructure compliance launch. for roadmap have We our plans

a all significantly of building healthcare listening which advocacy ensure plan. patients, established launch strong execution, and to integrated To been professionals, have has cross-functional aligned our an and community. the team, And informed we by activities launch payers, an been

we results. year advance and ahead, Phase to finalize readiness the plans of in is continue launch we XXXX As X as look to execute our the

large are had year. a from start robust completed input a We experts. project U.S. This off goals. claims to with We and project, already two strong recently this insurance

U.S. treatment The projected improve goal refine our to population characteristics. and prevalence demographics patient first and of further of the knowledge was SBS-IF

growing. estimate patients who are adult for least surgical resections have X,XXX SBS-IF living at months. and in with the had We are the parenteral patients chronic of now support be and on number to U.S. continuous and These six

We SBS-IF also U.S. patients with in pediatric estimate living X,XXX the an additional X,XXX to

a primary very project of they where commercial the the and care seek account are more and Account to We actionable targeting good accurate who SBS-IF understanding list established a now have targeting is strategy. goal was have takes multi-disciplinary generate for treated our physician and targeting support that patients information of the level our being will and of prioritized treating the patients. deployment second The at be we team go-to-market as approach level. to

field information our this later and We the for work, force structure as basis will use begin will size which this year.

and activities forward to update of planning continue to plans. our to pre-launch look be track We the on progress for all you on continuing

that, to I over now turn Claudia? Claudia D'Augusta CFO, results. discuss With our will financial call the to our XXXX

Claudia D'Augusta

you, Kevin. Thank

I recognized with AKP. the will the to for briefly key on Agreement year contracts the from now XXXX, over revenue with $XX.X year XXXX. XXst, financials Partnering million We customers the December of related ended comment

and Nutrition $XX and Research was of and XXXX. December Graft-Versus-Host $XX.X clinical proof our The SBS-IF study chamber Phase to X development of million Acute compared concept the Disease XXst, December expenses as of study, an expenses manufacturing STARS XXXX, patients, million in activities. STARGAZE year-over-year XXst, to the the ended on the increase of syringe to were progress year million related apraglutide primarily study for dual due year the X made $XX.X increase million in ended Phase STARS for the $XX.X of

liabilities offset XXXX. An an of decrease by driven the the million of by caused million of the of the impact with increase share-based expenses in the increase related increase primarily in $X.X of to of of revaluation compensation contingent gain employee expenses payroll $X.X partially million employee headcount, million, a $X.X and $X.X non-cash in recognized

to of million ended General compensation expenses XXXX, offset million, was expenses year by decrease share-based mainly with non-cash expenses for were $X.X attributable of headcount the an ended to in $XX.X million, million, an of increase in December XX, of professional and $X.X of decrease million $X.X the compared for increase of and decrease a $X.X payroll mainly due caused million in year-over-year in increase the corporate the partially primarily expenses a by services activities. to $X.X $XX.X employee XX, million employee an December driven administrative year The XXXX.

into million expenses XXXX. current to as cash and operating December cash we requirements cash enable expenditure our $XXX.X XX, equivalents were operating XXXX. Based $XXX.X us XXXX, our as that of capital and million XX, estimate plan, December our Cash to existing compared fund equivalents upon of will and

like to the Luca. I'd Now, hand call to back

Luca Santarelli

Thank you, Claudia.

three of to underscore and following We close, points. covered during like call I'd the ground a lot today's to

readout year in First, perhaps we XXXX weeks the and Phase including our followed of STARGAZE X for most a important X importantly will the analysis VectivBio Phase to by for promises data datasets, the as results of couple study a be Nutrition just six-months transformational interim study. then STARS topline

comprehensive failure. operating past position a of executing Phase are with And of the plan a us readout of takes X that than the intestinal blockbuster we're launch runway Second, strength achieving a XX study. with launch cash SBS from a apraglutide line of in we STARS aim financial finally, months preparation the top more

Operator? to call for with like the And that, questions. we open would

Operator

Instructions] comes [Operator The question Piper Sandler. first Allison Bratzel with from

open. now is line Your

Allison Bratzel

for guys, Hi, thanks and good taking questions. the morning,

next other the or benefits could to measures, parenteral what weight going the population? available frame APRA of data you support be just in and that. STARS just weight, most question then after a us to addition the So, reduction And do scope CIC on metrics illustrating have follow-up first going that's DDW, update at to be absorption the are in just of important months to what body for the Nutrition I

Patrick Malloy

your How today. to Hi, question. we have about on Allison, first jumping thanks the Omar to question. for Thanks handle

Omar Khwaja

Yes, thanks, Allison.

that happened body So also at also changed mass months patient's reduction the the energy a PS over show of of weight the over as that's PS then the calories and the PS and DDW well timeframe. the volume how the over in content as six period what number to will

Allison Bratzel

for larger to then broadly. on on role describe just see read you established like the to feel data what diseases of And UC just need Crohn's out your your And also quarter, to in proof and of like indications of GI kind you've the you informs thinking of frame STARGAZE I'm interim of in can GvHD just this hoping and just principle there? STARGAZE us you've like kind you strategy Great. feel in opportunity proof could established inflammatory or more the the and on also APRA how concept

Patrick Malloy

Great.

have we'll question. that take think I Luca

Luca Santarelli

Thanks, Alli.

rates the report months assessing, in So, previous that for in overall two we'll terms indication. precedent we what example, which will month likely response, response both of drug durability on and obviously analysis, effects the in of Ruxolitinib this trials one as have report a of from and endpoints

in Germany in data datasets bar the the And with Incyte has REACH-X REACH-X the and by exact been have in their set as able past, both that access as was trial Novartis and the U.S. in been generated and well other that we to

extract the standard group And of -- datasets GI The care of we which steroid patients course GvHD. as have XX% of And that those as able that refractory will datasets. create importance of combined and because -- all steroids. such comparator of among we're the those Ruxolitinib patients we to in all from symptoms about represents those had

appropriate So, dataset. very it's a

that that as we'll bar is, In finalized. soon terms -- communicate as datasets where the those of we have

would intestine of say, to that combining I start that saying of this indications, terms the would immunosuppression. we're healing first, In is like of and novelty I clearly well, by the intestine of regeneration approach the with new

in So, is and crucial patients is such from the alloimmune steroids dampen immunosuppression inhibitors. response the JAK engrafted achieved to as by tissue other these immunosuppressants and

adds GLP-X guttery absorption, care, growth are in increased that then those of the mechanism. function, combine of And as healing, improvement barrier with of known GLP-X part you well which combine to the you features mechanism, standard be those as all

comes will would combining of in existing therapy, the these and apraglutide can line concept But had standard opportunity cost be least that similar next of it's or notion at our think the and is to intestine anti-TNFs are when course, anti-integrins of example, drug that with be be care the we extended condition it immunological to the proof indication in or that additional that this they of and looking the importance for immunosuppressant place for of to this second the this indications. biologics currently

Allison Bratzel

one one. And just maybe Great. last

status talked for pre-filled us to just syringe data I you've of And what's pre-filled that? remind or need a syringe sense of of Could the you kind for approved? Thanks. APRA a our what syringe. kind just of to generate about think you dosing if developing you get

Luca Santarelli

Yes.

is XXXX So, launching device, that we're timelines we're such device with a in developing a compatible, the combination. with drug

case -- development is human launch bioavailability syringe of or validation Phase including our launch of work in to conduct and series is prefilled going studies the main the with So X. [indiscernible] planned including purely through all progressing is the base and our programs and chamber to case the studies studies, the is dual this of on side syringe. in with that We're CMC a studies that factor parallel are of

We will the required be have completed is start relative the GMP to bioavailability manufacturing study for due imminently. that which

for on time a syringe. launch basically dual-chamber we're with So, the

Allison Bratzel

Thank Excellent. you.

Operator

next comes with Please of Bank our question America. from standby for question. The next Tazeen Ahmad

line Your open. is now

Tazeen Ahmad

for my a Thanks guys. Hi, have much questions. couple. so I taking

competitors? apraglutide better us already So, like inbounds maybe lot the you you CIC STARS for conceptually, on particular follow-up. mechanistically that you. landscape Obviously, is CIC has would And of the what's specifically with open getting CIC, Luca, help market into we've patients a chance the if higher population a of but success it relative could been have think you interest to think I to competitive a frame enrolled explain in rate why wide us just can the showing study. then Thank and for in I is from

Luca Santarelli

one reasons. design -- Well, specific. other design trial is the is is -- reason One there's that and two molecule specific

affinity think, response terms line, of way in we studies is speaking, as So perhaps one has that more potent more important, and half-life in make it patients. distinct not features our comes comes and different pharmacologically a point the the is patients patients. receptor in drug it stoma to CIC the just that of shown if as I this believe like preclinical head-to-head physiologically pharmacology molecule to when published display it when actually from to then both important, to molecule, the They Stoma from are greatest

sensitivity that detecting the that for be have patients deployed response for and of the And the shown Stoma for support patients. in to the methodology trial all clinical perfected CIC testing parenteral Nutritional as The for while in but evolved was not we patients. adjusting methodology basically was our trials time in CIC response increase first methodology

more chains the and diuresis consistency, molecular tracking on the critical are a to key absorption the we apraglutide balance their less focus of frequency body for of of to nature both well changes. which fluid Stoma. stool, their in in design. of specific response and aspects terms essentially the used So of enhancing trial trial. to more because are methodology changes of on their course, metabolism, patients, the seeing or other be changes is differentiation the their the In are of in weight, words, more CIC as fluids, response Those as And, for so the

add the persistency, of to use and the market. able And adherence Tazeen, our and sub-types and drug the inform increase drug a that fashion critical in in ease patient two of is the the also would on treatment for objectives are use fact bespoke lastly, being compliance which tailored once that, will to I to ethe the in fashion a

past patients, appropriate left the the been the make has of pioneering from think something help experience more to easier we and on the of experiences with Gattex. So use that table

Tazeen Ahmad

necessary that's there we the might You CIC? about should Is as there you patients. certain But in it to of for for looking those are anything this be those relates observations off that data be talked order at some meaningful to results for STARS Okay, the topline as relates important it in are think that to for clinically be cut considered that super subgroup? more that that helpful. endpoints,

Luca Santarelli

put in emphasis. subgroup, a Well, we of a CIC lot

is The fluid changes couple timeline all, focused are on bit aspects there's longer. of or different and more less the First is it response a that on changes relevant. metabolic a of

for X trial to for So patient. the and trial the been be done quick That's and why double be ran Nutrition Stoma what of this expectation we've the it is we tempered what our our XX past. has response, Phase very done in should duration add a for weeks

effects accrue The is, expect six to stop to beyond not other point six we months the months.

there the and and way beyond the beyond months record basically likely to hope six for likely in can timeframe. So, we still STARS for then point maybe to to nine on is patients will to XX why the benefit for Phase that's trial month size we be again that we a this able kept X these weeks. a And we patients demonstrate six treatment blinded all larger effect months group XX-months

for days a can enemy In infusion likely are able within because terms come patients patients. to more period. what as dehydrate outcomes XX-hour is being are they dehydration of of are relevant of as key off, one these readily more course, to because dehydrate of STARS is to very quickly days patients, The that these don't off able a shave being

a again start days full average from Stoma autonomy from the top which same fewer so of we we then less so CIC a patients. at is days win for or hierarchy. is that crucial than And point Again it our for reason more achieving obviously propensity another of of the complete achievable think off they autonomy have a these enteral dehydrate, And potentially infusion, for week patients. it's to have on support, is enteral it's parenteral easier secondly, for a endpoint off

Tazeen Ahmad

Luca. Okay, perfect. Thanks,

Operator

Please question from question. comes Securities. The standby SVB for our next Smith, next Thomas

now line Your open. is

Thomas Smith

can STARS pivotal a Couple in on there reduction PF program, Hi, the making taking the progress. in questions specific who question do CIC and the that We on you're CIC on patients the to for the of you of patients. in and arm fluid in the all the expect I Good trial relied guess some assumptions powering volume congrats CIC, And treatment to a STARS endpoints? morning. only our placebo using XX% effects questions on algorithm received placebo what and for the guys. relative for and Thanks study? was assumptions follow-up respond Gattex balance. algorithm us end. the but to How first your the was titration anatomy know you Gattex that the remind assumed of the changes for

Luca Santarelli

Thanks the for question.

basically increase which we're of in the algorithm the the the responses also should winning just the we not this So are sensitivity detection -- to with -- the designed significantly changed CIC, population. response mechanisms but changed optimization that reduce placebo we've have

was Essentially, was what of average requiring oral less of GLP-X trial the observed nutrition to this was support attributable of in on nutrition, past a because XX%, treatment support patients better parenteral XX% nutrition. which parenteral irrespective or placebo response, that the course optimization the a of during

of receiving invested have they stable drug. start time making and So before and we significant patients these very in amount optimized effort

subgroup. winning these placebo tested the So more again, the in so significant nutrition reduction algorithm which signal the already CIC give factors, us and are two response a in predicted we trial to

was for for we it placebo in CIC, of towards an overall XX% active. what the specifically but a powered would effect powered powered I to about Now, study the say and we CIC have we terms the the -- powered delta between size,

XX%. relatively seen have in are here. for aiming trial So would What data that indicate big the delta we that nutrition as be could it's as we a the small

number these more and are diminishes. run that assume on sites to when a we you an that typically large delta simply But because large number of of we of and course, countries, have placebo-controlled large between a may get trial, active not patient the [female] trials placebo in

assume there. So, of reduction is that we XX% nutritionally close has you the think which placebo if XX% about about delta XX% a to

of that case sort the be scenario. I best think will

Thomas Smith

competitive And Can and up GLP-X update next for Great. over the landscape That's just generic see on market five three super Got you it. just SBS. on and shaping the expectations then to helpful. us how competing you latest the in your one programs years? Gattex

Luca Santarelli

then start Kevin allow I'll continue. I'll and Yes.

here. In our confident terms of competitive a sponsors our expectations We're other very we have using comment package programs. were the from about

company a only are the We weekly drug. with

only We very this anatomical ability we for to discriminate are the between company an with subtypes, is different think which crucial population.

the specifically we are company a for designed this outcomes are reported of significant patient And population. that that that has only were amount bespoke

so molecule to we're combine have And our know there's and others, very very the confident, what differentiation. that we versus plenty we about a high if with you chance

have he In lot think further in the this are because the landscape, work comment has into on Kevin? I'll of advanced that generic Kevin space. done so a terms of of generalization Gattex. I now we

Kevin Harris

Thanks, Luca. Yes.

As would for you There's we in haven't the at may challenges and be know, there profile reasons and a have possibility think of why which a -- generics. aware clearly to generic limited the of year under this market approach required manufacturing, guidelines or Gattex have manufacturing and pretty significant one require launch may a been both point. half for for to to CMC transitioning synthetic one particular and of, attractiveness lot second Gattex the of of could the of Gattex some today in would March has overcome be emerge that in this seen from recombinant We SBS-IF investment. the there's

on patients effort some keep to take treatment. them and identify does It to

As by two-thirds discontinue shown and and month persistency have Gattex There significant challenges XX. requirements registry up to half month by on and we've of them for is with REMs Gattex. patients XX

And so approval. and paragraph have We've an one the think done generics. some not the to filing only we yet and in factors attractive seen seen these isn't particularly for why we of was are that still back just XXXX for market date

Luca end to corporation a a to lot dosing support whether that we've they to the we at differentiation will very come we'll to mentioned, And If dose be being come drug. and day, think as able view So, Gattex be And remains payers. of the seen of generic generic without a yes, market, efficacy would had does provide. on obviously on as one significant market. one a with demonstrate weekly I Gattex the significant engagement believe

see don't the apraglutide threat have that we to So a generic SBS-IF. we a in as opportunity think strategic

Thomas Smith

helpful. taking That's super the guys, for Thanks, questions. it. Got

Operator

next our for standby question. Please

question comes Our LifeSci from next Patrick with Capital. Dolezal

open. now is line Your

Patrick Dolezal

It's cohorts. the questions. interesting of kind CIC for thinking bit the a taking for thanks and the little of longer waiting enrollment now stoma Hi, speed about

curious, design how relative kind strategy versus Gattex receiving pivotal of and what's ultimately currently CIC and Just the trial of might proportion your ratio stoma time? this over marketing patients shift

Luca Santarelli

Yes.

So, Patrick. hi,

to can So of on that countries our U.S. different both in in we've study information leading that's research have XX that, experience basically done the including conducting and work we own and in -- including the Europe. we feasibility are market up we rely sources

the keeping of CIC importance of greater the patients of first with impact estimate portion fluids. absorbing at population since on launch the call Gattex of have increased provide to to the ability least appreciation of the So we a of because

so in anywhere CIC between have number an of that we the proportion. XX%. We XX% And be seen to estimate increase could

know XX% We that's would fair exact the stoma. but don't number, exactly the other say, would a the around And what of, with I versus was estimate be many XX%, XX% be sort question? obviously part of not now

Patrick Dolezal

it how impact was, marketing it may our think I approach.

Luca Santarelli

Okay.

So -- have maybe we'll

Patrick Malloy

Yes. Kevin, the do the you question? want part second to of take

Kevin Harris

frequently analysis at that patients obviously and always that Gattex suggest Gattex is of we've got CIC than X.X stoma used data CIC to that times to And X a in been have least patients more so that represents Yes. points couple in times demonstrate in We underserved. retrospective of didn't have any majority these that effect population. a the seen believed we've recognizing

population. Gattex, good the have in also the of efficacy a We that lack main is in drivers of is which one CIC discontinuation understanding of particular for that

really of needs So address unmet better our product anatomy. strategy obviously by a to the beyond much is pharmacology with having

population, getting market because room half our of research potential for that in long-term getting today. are growth apraglutide by and potential that Gattex the can of CIC be certainly patients of only really of There's patients, indicated Gattex driven stoma XX% market significantly to less that significant still population might but the XX% fraction than growth be the a in whom

So the prospective CIC uniquely our CIC the trial to patient APRA's be the able earlier, off APRA, not days position appropriately autonomy design and endpoints in think benefits be of and into as of with us of only to best anatomy to demonstrate our to alpha mentioned X measure the our manner, until to population ability people able off controlled whine in Phase specific educate promote PS. effect a but and how on I Luca proactively

So strategy and commercial I we're think development marketing I between and very tight well strategy, for think our our positioned there's integration and success.

Patrick Dolezal

could the GI us effects guys patient And for is it. in And have just and through trial data you involvement just level STARGAZE features? then, match you other how curious, particular disease arm how characteristics kind the of handled? Do of walk to Got outcomes? kind GvHD, control in propensity

Omar Khwaja

Patrick. Thanks, Yes.

life quiet targets and develop patients are often liver is skin the is condition, and actual the particularly in denude which in transplant and so basically are to osmotic preparation to that their which which the that the toxic attack And graft a continuing conditioning for the gut the donor post-transplant, to that diarrhea. profound undergoes stem the GI tissue. leads gut to and gut primary contained their for there that's that is leads and mucosal So bile tract itself in got the to the of host patients that. the threatening And in injuries T-cells, salts being inflammatory which epithelium, cell providing a the then

the the And barrier of the well will stress. other itself is from becomes bacteria barrier patients intestinal across as problem transportation so the bloodstream, into gut and impaired that and gut the lumen develop becomes

population. the GI reasonably scale need unmet probably the level it's and tract proportion mortality of addressed well significant gut that kind the though were remains account but to significant So typically immunosuppression of the with a thought in are for

Patrick Malloy

much. that question? so Thanks answer your is Great. Patrick,

Patrick Dolezal

And arm what propensity your then - the control Yes. I conduct was second, guess match

Omar Khwaja

do outcomes is Stargaze. score to compare well matched used from we to have a and we've got synthetic our matched the level propensity basically control ensure data so that patient and Yes,

Patrick Dolezal

you. Got it, perfect. Thank

Operator

now show time. questions further like turn back to I at no to for would Santarelli I this conference closing remarks. Luca the

Luca Santarelli

all better to Thanks to participating, to for people insightful helping the us continue Thank a in questions participated Q&A your for everybody and for company. and the that you. become

Operator

for This you call. Thank concludes today's conference participating.

now may You disconnect.

VectivBio Holding (VECT) 19 Apr 232022 Q4 Earnings call transcript